Witnessing the stock’s movement on the chart, on Wednesday, Seres Therapeutics Inc (NASDAQ: MCRB) had a quiet start as it plunged -3.51% to $0.69, before settling in for the price of $0.72 at the close. Taking a more long-term approach, MCRB posted a 52-week range of $0.54-$1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 477.44% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 18.22%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 86.52%. This publicly-traded company’s shares outstanding now amounts to $170.20 million, simultaneously with a float of $127.27 million. The organization now has a market capitalization sitting at $120.69 million. At the time of writing, stock’s 50-day Moving Average stood at $0.8031, while the 200-day Moving Average is $0.8765.
Seres Therapeutics Inc (MCRB) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Seres Therapeutics Inc’s current insider ownership accounts for 26.90%, in contrast to 22.97% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s insider sold 3,338 shares at the rate of 0.81, making the entire transaction reach 2,704 in total value, affecting insider ownership by 97,536. Preceding that transaction, on Feb 18 ’25, Company’s insider sold 3,953 for 0.81, making the whole transaction’s value amount to 3,204. This particular insider is now the holder of 84,443 in total.
Seres Therapeutics Inc (MCRB) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
Seres Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 86.52% and is forecasted to reach -0.33 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 25.41% through the next 5 years, which can be compared against the 18.22% growth it accomplished over the previous five years trading on the market.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Let’s observe the current performance indicators for Seres Therapeutics Inc (MCRB). It’s Quick Ratio in the last reported quarter now stands at 1.12. The Stock has managed to achieve an average true range (ATR) of 0.06. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2011.54.
In the same vein, MCRB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.19, a figure that is expected to reach -0.20 in the next quarter, and analysts are predicting that it will be -0.33 at the market close of one year from today.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Going through the that latest performance of [Seres Therapeutics Inc, MCRB]. Its last 5-days volume of 0.52 million was inferior to the volume of 1.4 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 52.76% While, its Average True Range was 0.0600.
Raw Stochastic average of Seres Therapeutics Inc (MCRB) in the period of the previous 100 days is set at 32.51%, which indicates a major rise in contrast to 31.57% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 85.41% that was lower than 89.30% volatility it exhibited in the past 100-days period.
